Definition and pharmacological basis
Ezetimibe is a non-statin lipid-lowering agent that inhibits the Niemann–Pick C1-like 1 (NPC1L1) transporter in the intestine. By reducing intestinal cholesterol absorption, it decreases the quantity of cholesterol delivered to the liver. The resulting hepatic response includes increased expression of low-density lipoprotein receptors (LDLRs), which enhances removal of circulating LDL particles.
Its principal clinical effect is therefore reduction of LDL cholesterol (LDL-C), through a mechanism complementary to that of statins. Statins reduce hepatic cholesterol synthesis, whereas ezetimibe limits intestinal cholesterol uptake.
Expected LDL-C reduction
Ezetimibe produces a modest LDL-C reduction when used alone and a further reduction when added to statin therapy.
| Treatment regimen | Expected LDL-C reduction |
|---|---|
| Ezetimibe monotherapy | Up to 20% |
| Ezetimibe added to a statin | Additional 15–20% |
| Ezetimibe with simvastatin after recent ACS | Approximately 20–25% additional reduction compared with simvastatin monotherapy |
| Bempedoic acid plus ezetimibe | Approximately 38% reduction |
| PCSK9 inhibitor added to statin therapy | Approximately 60% reduction |
| Inclisiran, with or without statin therapy | Approximately 50% reduction |
The absolute reduction depends on the pretreatment LDL-C concentration and the accompanying lipid-lowering regimen. Ezetimibe is particularly relevant when the residual LDL-C reduction required is greater than can reasonably be obtained with a statin alone but does not necessarily require the larger effect of a PCSK9 inhibitor.
Place in lipid-lowering therapy
General treatment sequence
High-intensity statin therapy remains the foundation of lipid-lowering treatment for patients with chronic coronary syndrome, acute coronary syndrome (ACS), atherosclerotic peripheral arterial disease, and other very-high-risk settings described in the source material. The statin should be prescribed at the highest tolerated dose.
When LDL-C remains above target despite maximally tolerated statin therapy, ezetimibe is the preferred initial combination drug. It is also an appropriate first-line pharmacological option when a patient is unable to tolerate any statin regimen.
The treatment sequence for patients with chronic coronary syndrome is:
Lifestyle intervention and a maximally tolerated high-intensity statin.
Add ezetimibe if the LDL-C goal is not achieved.
Add a PCSK9 inhibitor if the goal remains unmet despite maximally tolerated statin plus ezetimibe.
Consider bempedoic acid in selected patients, particularly those with statin intolerance or persistent failure to reach goal.
For statin-intolerant patients, ezetimibe may be used initially. If LDL-C remains above target, bempedoic acid is recommended in the relevant guideline setting; combination with a PCSK9 inhibitor is also described for high-risk patients with atherosclerotic peripheral arterial disease.
Chronic coronary syndrome
Patients with chronic coronary syndrome are considered to be at very high cardiovascular risk. The recommended LDL-C objective is:
LDL-C <1.4 mmol/L (<55 mg/dL), and
at least a 50% reduction from baseline.
For a patient who experiences a recurrent atherothrombotic event while receiving maximally tolerated statin therapy, an LDL-C goal below 1.0 mmol/L (<40 mg/dL) may be considered. The cited recommendations describe recurrence within 2 years in some clinical settings, while the broader lipid-lowering recommendation refers to a recurrent event without requiring that it be of the same type as the initial event.
Ezetimibe is recommended when the LDL-C target is not achieved with the maximum tolerated statin dose. This recommendation carries Class I status with Level B evidence in the chronic coronary syndrome lipid-lowering recommendations.
Acute coronary syndrome
The period immediately following ACS is associated with particularly high risk of recurrent cardiovascular events. Intensive LDL-C lowering should therefore begin early rather than being deferred until outpatient follow-up.
High-dose statin treatment should be initiated or continued as early as possible, irrespective of the initial LDL-C concentration. In patients already receiving lipid-lowering treatment before admission, therapy should be intensified during the index hospitalization.
Ezetimibe can be added during the ACS admission in several circumstances:
when the patient is already receiving a maximally tolerated statin and is unlikely to reach the LDL-C target with statin therapy alone;
when the patient was not previously taking a statin but is unlikely to achieve goal with high-intensity statin monotherapy;
when the patient was receiving lower- or moderate-intensity statin treatment before ACS and requires treatment intensification.
Guideline recommendations state that adding ezetimibe after 4–6 weeks of maximally tolerated statin therapy is recommended when the LDL-C goal has not been attained. In addition, initiation of high-intensity statin plus ezetimibe during the index hospitalization should be considered in treatment-naïve ACS patients who are not expected to reach target with statin therapy alone.
Where a patient was already receiving statin plus ezetimibe before admission and remains above target, a PCSK9 inhibitor should be initiated during ACS hospitalization according to the cited recommendations.
Diabetes mellitus
The combination of ezetimibe and a statin has particular relevance in patients with diabetes and recent ACS. In the IMPROVE-IT population, the reduction in major adverse cardiovascular events was greater in the diabetes subgroup than in the overall cohort.
Patients with type 1 diabetes may have increased cholesterol absorption compared with those with type 2 diabetes. This provides a pharmacological rationale for potentially greater efficacy of ezetimibe in type 1 diabetes, although the source material notes that dedicated randomized trials are still required to assess this specifically.
In younger patients with type 1 diabetes, early statin treatment may be justified when disease duration is long, two additional risk factors are present, or microalbuminuria exists. Ezetimibe may be particularly useful when LDL-C remains above goal despite statin therapy.
Atherosclerotic peripheral arterial disease
Lipid-lowering therapy is recommended for patients with atherosclerotic peripheral arterial disease. The LDL-C goal is <1.4 mmol/L (<55 mg/dL), together with a reduction of more than 50% from baseline.
Statins are recommended for all patients with peripheral arterial disease. If the LDL-C target is not reached with maximally tolerated statin therapy, adding ezetimibe is indicated. If the combination remains inadequate, a PCSK9 inhibitor is recommended.
For statin-intolerant patients at high cardiovascular risk who do not achieve the LDL-C goal with ezetimibe, bempedoic acid may be added either alone or in combination with a PCSK9 inhibitor.
Clinical evidence for cardiovascular benefit
In patients with recent ACS, adding ezetimibe to statin therapy has demonstrated cardiovascular benefit in addition to LDL-C lowering.
In IMPROVE-IT, 18,144 patients with a recent ACS and baseline LDL-C values between 50 and 125 mg/dL (1.3–3.2 mmol/L) were treated with statin therapy with or without ezetimibe. Ezetimibe was administered at 10 mg/day. During 7 years of follow-up, the combination produced an additional relative reduction of 6.4% in atherosclerotic cardiovascular disease events.
The guideline-defined major adverse cardiovascular event outcome included cardiovascular death, non-fatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization performed at least 30 days after randomization, or non-fatal stroke. In the guideline summary, simvastatin plus ezetimibe reduced this composite outcome compared with simvastatin alone, with a hazard ratio of 0.94 and a 95% confidence interval of 0.89–0.99. The treatment effect was more pronounced among patients with diabetes, in whom the hazard ratio was 0.85 with a 95% confidence interval of 0.78–0.94.
The absolute benefit was described as modest, with an absolute risk reduction of 2.0% in the cited ACS context. Nevertheless, the results support the principle that additional LDL-C lowering with ezetimibe provides incremental outcome benefit when added to statin therapy.
A study comparing moderate-intensity statin plus ezetimibe with high-intensity statin monotherapy found non-inferiority of the combination for a 3-year composite outcome. The combination arm included a greater proportion of patients achieving LDL-C <70 mg/dL and had fewer intolerance-related discontinuations or dose reductions. This finding supports the use of combination therapy when a high-intensity statin is poorly tolerated or insufficiently effective.
Drug use and practical prescribing
Dose
The dose specifically provided in the source material is:
- Ezetimibe 10 mg once daily
This was the dose used in the ACS outcomes evidence summarized above.
Ezetimibe is commonly used with a statin, either as separate tablets or in a fixed-dose combination. Fixed-dose combinations involving statins and bempedoic acid are also available, although specific product doses are not provided in the source material.
Combination with statins
Ezetimibe should generally be combined with the highest tolerated statin dose when the patient can take a statin. The combination is pharmacologically complementary and provides an additional LDL-C reduction of approximately 15–20%.
The available evidence indicates that adding ezetimibe to a statin does not increase creatine kinase elevations or muscle adverse events compared with statin therapy alone. This is clinically important when treatment escalation is needed in patients concerned about muscle symptoms or unable to tolerate higher statin doses.
Statin intolerance
For patients unable to tolerate any statin regimen, ezetimibe may be used as first-line non-statin therapy. If the LDL-C goal remains unmet, the cited recommendations support adding bempedoic acid. In high- or very-high-risk patients, other non-statin agents with demonstrated cardiovascular benefit may be selected according to the magnitude of LDL-C reduction required.
Hepatic and muscle safety
Life-threatening hepatic failure associated with ezetimibe is described as very rare. Addition of ezetimibe to statin therapy did not produce more creatine kinase elevations or muscle adverse events than statin monotherapy in the evidence summarized.
Lipid levels should be reassessed after treatment initiation or modification, with attention to safety issues and tolerability. The ACS recommendations specify reassessment after 4–6 weeks.
Guideline recommendations
Chronic coronary syndrome
| Recommendation | Class | Level |
|---|---|---|
| Aim for LDL-C <1.4 mmol/L (<55 mg/dL) and a reduction of at least 50% from baseline | I | A |
| Use high-intensity statin therapy up to the highest tolerated dose | I | A |
| Add ezetimibe when the LDL-C goal is not achieved with the maximum tolerated statin dose | I | B |
| Add a PCSK9 inhibitor when the goal is not achieved with maximally tolerated statin plus ezetimibe | I | A |
| Consider bempedoic acid with maximally tolerated statin plus ezetimibe when the LDL-C goal remains unmet | IIa | C |
| Consider LDL-C <1.0 mmol/L (<40 mg/dL) after a recurrent atherothrombotic event on maximally tolerated statin therapy | IIb | B |
Acute coronary syndrome
| Recommendation | Class | Level |
|---|---|---|
| Initiate or continue high-dose statin therapy as early as possible, regardless of initial LDL-C | I | A |
| Aim for LDL-C <1.4 mmol/L (<55 mg/dL) and at least a 50% reduction from baseline | I | A |
| Add ezetimibe if the LDL-C target is not achieved after 4–6 weeks of maximally tolerated statin therapy | I | B |
| Intensify lipid-lowering therapy during the index hospitalization in patients already receiving lipid-lowering therapy | I | C |
| Consider high-dose statin plus ezetimibe during the index hospitalization in treatment-naïve patients unlikely to reach goal with statin alone | IIa | B |
| Add a PCSK9 inhibitor if the LDL-C goal is not reached despite maximally tolerated statin plus ezetimibe | I | A |
| Consider LDL-C <1.0 mmol/L (<40 mg/dL) after recurrent atherothrombotic events in the specified high-risk setting | IIb | B |
Peripheral arterial disease
| Recommendation | Class | Level |
|---|---|---|
| Use lipid-lowering therapy in atherosclerotic peripheral arterial disease | I | A |
| Aim for LDL-C <1.4 mmol/L (<55 mg/dL) and a reduction greater than 50% from baseline | I | A |
| Use a statin in all patients with peripheral arterial disease | I | A |
| Add ezetimibe when the LDL-C target is not achieved with maximally tolerated statin therapy | I | B |
| Add a PCSK9 inhibitor if the target remains unmet despite maximally tolerated statin plus ezetimibe | I | A |
| In statin-intolerant, high-risk patients, add bempedoic acid when ezetimibe alone is insufficient | I | B |
Monitoring and follow-up
LDL-C should be checked 4–6 weeks after initiation or intensification of treatment and after each subsequent treatment adjustment. The assessment should determine:
whether the LDL-C goal has been reached;
whether the required percentage reduction from baseline has been achieved;
whether treatment is tolerated;
whether safety concerns require modification of the regimen.
Following ACS, lipid-lowering therapy should be maintained lifelong with the objective of sustaining the recommended LDL-C target. Early treatment initiation is emphasized because the post-ACS period is particularly vulnerable and delays in intensification may prolong exposure to inadequately controlled LDL-C.
Follow-up should also address adherence, since prescription inertia, adverse effects, reluctance to use statins, and delayed post-discharge review may all contribute to failure to achieve LDL-C targets. A polypill may be considered as an adherence-enhancing strategy in secondary prevention after ACS.
Lifestyle and comprehensive risk reduction
Ezetimibe should be integrated into a broader cardiovascular prevention programme rather than used as an isolated intervention. The cited recommendations emphasize:
complete tobacco cessation;
a healthy, Mediterranean-style diet;
restriction of alcohol;
regular aerobic and resistance exercise;
reduction of sedentary time;
weight control;
participation in structured, medically supervised cardiac rehabilitation after ACS.
For smokers, follow-up support and pharmacological cessation therapy with nicotine replacement, varenicline, or bupropion may be considered, individually or in combination.
Prognosis
The prognostic value of ezetimibe is best established in combination with statin therapy in patients with recent ACS. The incremental reduction in major cardiovascular events is modest in absolute terms but clinically meaningful, particularly in patients who remain above stringent LDL-C targets despite statin therapy.
The benefit is consistent with the broader treatment principle that lower LDL-C is associated with lower cardiovascular event rates. It is also relevant across clinical subgroups described in the source material, including patients with diabetes, peripheral arterial disease, and women, in whom the relative effects of ezetimibe added to high-intensity statin therapy are reported to be similar to those observed in men.
Ezetimibe therefore occupies a central second-line position after maximally tolerated statin therapy and a first-line role among patients who cannot tolerate statins. Its modest LDL-C-lowering effect, demonstrated outcome benefit, complementary mechanism, and favourable muscle and hepatic safety profile make it the preferred initial non-statin combination agent in most patients who do not achieve target LDL-C with statin therapy alone.
